Skip to content

Umbralisib

Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: TGR-1202, ukoniq, umbralisib tosylate

OfmFDA approvedOrphan designationATC L01EX25

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Umbralisib is an ofm drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Kinase Inhibitors. DrugCentral lists 5 molecular targets, including PIK3CD, CSNK1E and PIK3CG. Recorded indications include Relapsed or refractory follicular lymphoma and Relapsed or refractory marginal zone lymphoma.

  • Approval status: ofm (first approved 2021 by the FDA).
  • Drug class: Kinase Inhibitor.
  • Mechanism of action: Kinase Inhibitors.
  • Molecular targets: PIK3CD, CSNK1E, PIK3CG and PIK3CA (5 listed in DrugCentral).
  • Indications: Relapsed or refractory follicular lymphoma and Relapsed or refractory marginal zone lymphoma.
  • ATC code: L01EX25 (Other protein kinase inhibitors).
  • Molecular formula: C31H24F3N5O3; molecular weight 571.56 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Relapsed or refractory follicular lymphoma
  • Relapsed or refractory marginal zone lymphoma

Mechanism & targets

Mechanism of action (MoA)Kinase Inhibitors
Established pharmacologic classKinase Inhibitor

Molecular targets (5)

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2021-02-05FDA—TG THERAPEUTICS IncYes

ATC classification

ATC codeTherapeutic hierarchy
L01EX25ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Nervous system disorder60.2
Immunodeficiency common variable49.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Umbralisib is on its molecule page.

Molecular formulaC31H24F3N5O3
Molecular weight571.56 g/mol
CAS number1532533-67-7
InChIKeyIUVCFHHAEHNCFT-INIZCTEOSA-N
PubChem CID72950888
C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Umbralisib used for?

DrugCentral lists the following indications for Umbralisib: Relapsed or refractory follicular lymphoma and Relapsed or refractory marginal zone lymphoma.

How does Umbralisib work?

Umbralisib is classified as Kinase Inhibitors; its molecular targets in DrugCentral include PIK3CD (inhibitor), CSNK1E (inhibitor), PIK3CG (inhibitor) and PIK3CA (inhibitor).

When was Umbralisib first approved?

Umbralisib was first approved by the FDA in 2021.

What drug class does Umbralisib belong to?

Umbralisib is in the Kinase Inhibitor class.

What is the chemical formula of Umbralisib?

Umbralisib has the molecular formula C31H24F3N5O3 and a molecular weight of 571.56 g/mol.

Browse: all drugs starting with U · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval2021-02-05
AgencyFDA
Targets5
Indications2
FormulaC31H24F3N5O3
DrugCentral ID5441
Interactive profile